Coherus BioSciences

 – Recognized biopharma commercialization and market access leader to support Coherus’ strategic vision and multiple…
Read More...

<!-- Name:DistributionId Value:8832592 --> <!--…
Read More...

- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all…
Read More...

- CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023…
Read More...

– CIMERLI™ BLA review progressing toward August 2022 action date –– Toripalimab BLA resubmission expected by mid-summer…
Read More...

REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”,…
Read More...

REDWOOD CITY, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today…
Read More...

– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary…
Read More...

- Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with…
Read More...

REDWOOD CITY, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq:…
Read More...